These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11236942)

  • 21. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
    Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
    Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts.
    Rellick SL; Piktel D; Walton C; Hall B; Petros W; Fortney JE; Gencheva M; Denvir J; Hobbs G; Craig M; Gibson LF
    Cytokine; 2012 May; 58(2):245-52. PubMed ID: 22356805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
    Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
    Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.
    Zheng Y; Cai Z; Wang S; Zhang X; Qian J; Hong S; Li H; Wang M; Yang J; Yi Q
    Blood; 2009 Oct; 114(17):3625-8. PubMed ID: 19710503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
    Tamura H; Ishibashi M; Yamashita T; Tanosaki S; Okuyama N; Kondo A; Hyodo H; Shinya E; Takahashi H; Dong H; Tamada K; Chen L; Dan K; Ogata K
    Leukemia; 2013 Feb; 27(2):464-72. PubMed ID: 22828443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
    Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment].
    Bernat S; Gozalbo T; García-Boyero R; Guinot M
    Sangre (Barc); 1998 Feb; 43(1):96-7. PubMed ID: 9577192
    [No Abstract]   [Full Text] [Related]  

  • 30. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 31. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
    Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
    Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human umbilical cord blood-derived stromal cells: a new resource for the proliferation and apoptosis of myeloma cells.
    Gao L; Zhang C; Zhang X; Gao L; Hao L; Chen XH
    Hematology; 2014 Apr; 19(3):148-57. PubMed ID: 23896383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
    Mitsiades CS; Rouleau C; Echart C; Menon K; Teicher B; Distaso M; Palumbo A; Boccadoro M; Anderson KC; Iacobelli M; Richardson PG
    Clin Cancer Res; 2009 Feb; 15(4):1210-21. PubMed ID: 19228727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
    Klein B; Seckinger A; Moehler T; Hose D
    Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
    Efferth T; Fabry U; Osieka R
    Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
    Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
    Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis.
    Liu P; Oken M; Van Ness B
    Leukemia; 1999 Mar; 13(3):473-80. PubMed ID: 10086739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.